First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study - Report - MDSpire
Advertisement
First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study
Clinical Report: Serplulimab Combined with Chemotherapy in SCLC with BM
Overview
This study evaluates the efficacy and safety of first-line serplulimab combined with chemotherapy in small-cell lung cancer (SCLC) patients with brain metastases (BM). Results indicate significant improvements in intracranial progression-free survival (iPFS) and overall survival (OS) compared to chemotherapy alone.
Background
Small-cell lung cancer (SCLC) frequently metastasizes to the brain, presenting significant treatment challenges and poor prognosis. Traditional therapies have limited efficacy due to inadequate penetration across the blood-brain barrier. The integration of immune checkpoint inhibitors like serplulimab may offer new therapeutic avenues for this high-risk population.
Data Highlights
Outcome
Serplulimab + Chemotherapy
Chemotherapy Alone
Median iPFS
8.93 months
6.37 months
Median OS
28.77 months
12.95 months
Intracranial Objective Response Rate
78.57%
N/A
Key Findings
Serplulimab combined with chemotherapy significantly improved median iPFS (8.93 vs. 6.37 months; P = 0.004).
The combination therapy also resulted in a notable increase in median OS (28.77 vs. 12.95 months; P < 0.001).
Patients receiving serplulimab achieved an intracranial objective response rate of 78.57%.
Adding cranial radiotherapy to the treatment regimen enhanced survival benefits.
No new safety signals were identified, indicating manageable safety profiles.
Clinical Implications
The findings support the use of serplulimab in combination with chemotherapy as a first-line treatment for SCLC patients with BM. The addition of cranial radiotherapy may further enhance treatment outcomes, warranting consideration in clinical decision-making.
Conclusion
First-line serplulimab plus chemotherapy demonstrates significant efficacy and manageable safety in SCLC patients with brain metastases, highlighting its potential as a viable treatment option.
